EnspryngWhat to know
30-second read
For Ophthalmology · Endocrinology
- Who
- Adults with thyroid eye disease (Graves’ orbitopathy) whose physician judges a home-injection regimen appropriate, with or without prior infused therapy.
- What’s new
- Satralizumab-mwge, already approved for NMOSD, is now the first at-home subcutaneous drug for thyroid eye disease — a third option alongside two infused biologics.
- Evidence
- Two identical Phase 3 trials, 258 adults: SatraGO-2 met its proptosis endpoint (52.9% vs 23.4%); SatraGO-1 missed it (49.0% vs 31.2%, P=0.0715).
- Big advantage
- Monthly self-injection at home after a loading series, replacing infusion-center visits every three weeks that both approved comparators still require.
- Key consideration
- Hepatitis B, tuberculosis and liver-enzyme screening are required before the first dose; one of two pivotal trials did not beat placebo on its own terms.
- Availability
- Approved 16 October 2026. No thyroid-eye-disease-specific billing code or payer policy confirmed yet; Enspryng’s existing NMOSD coverage uses an unclassified code.
Practice impactConsider for selected patients
A genuine access gain for patients who can self-inject and want out of an infusion chair — but a weaker pivotal trial and an unresolved reimbursement picture argue against switching a patient already doing well on an infused option.
FDA approved Enspryng (satralizumab-mwge) on 16 October 2026 as the first treatment for thyroid eye disease a patient can inject at home, following a priority review of Genentech’s supplemental application. It is the drug’s second confirmed U.S. indication since its 2020 approval for neuromyelitis optica spectrum disorder (NMOSD) — and it arrives with a complication the company’s own release does not hide: only one of its two pivotal trials met its primary endpoint.
Who actually qualifies for the home option
Thyroid eye disease (also called Graves’ orbitopathy) is the orbital inflammation that accompanies Graves’ disease in roughly a quarter to a third of patients: proptosis, eyelid retraction, diplopia and, in severe cases, compressive optic neuropathy. Until 2020 there was no FDA-approved drug built for the condition specifically; patients cycled through corticosteroids, selenium, orbital radiotherapy or decompression surgery. Teprotumumab (Tepezza) changed that in January 2020, and Viridian’s veligrotug (Lumvoa) followed in June 2026. Enspryng is the third approved option and the first that does not require an infusion chair.
Enspryng is an anti-IL-6 receptor monoclonal antibody — the same drug target class as tocilizumab, though a different molecule with a different label. FDA first approved it in 2020 for adults (and, outside the U.S., adolescents) with AQP4-antibody-positive NMOSD, an autoimmune disease of the optic nerve and spinal cord. The thyroid eye disease approval is a label expansion, not a new molecule, and the maintenance dose — one subcutaneous injection every four weeks, after a loading series at weeks 0, 2 and 4 — is a schedule most NMOSD prescribers already know. Genentech says a patient or a trained caregiver can give the injection at home using a prefilled syringe or a prefilled autoinjector, after instruction from a healthcare provider.
A trial program that split its own primary endpoint
SatraGO-1 and SatraGO-2 were identically designed: 72-week, double-masked, placebo-controlled Phase 3 trials enrolling adults with active or chronic inactive thyroid eye disease, randomized 1:1 to satralizumab or placebo, with a primary endpoint of proptosis response — at least a 2mm reduction in the study eye at Week 24 among patients with active disease. SatraGO-1 enrolled 131 patients; SatraGO-2 enrolled 127. Only SatraGO-2 reached statistical significance.
Proptosis response at Week 24, by trial
From Roche’s 16 October 2026 announcement and independent trade coverage of the published SatraGO results (Healio, Ophthalmology Times, Review of Optometry).
Investigators have attributed SatraGO-1’s miss to an unusually high placebo response rather than a weaker drug effect, and FDA evidently found the combined evidence — including a consistent, if smaller, benefit in the trial that missed — sufficient to approve. That is a judgment call physicians should be able to make for themselves: a 29-point absolute advantage over placebo in one trial and an 18-point advantage in the other both describe the same drug, but only one clears the conventional statistical bar. Safety was reported as consistent between the two trials and with the drug’s existing NMOSD experience through Week 24, with upper respiratory tract infection and elevated ALT the most common adverse events specific to the TED population.
The screening workup before the first dose
An IL-6 receptor antibody carries the infection and hepatic precautions of its class, and the label asks for a short workup before the first injection that an ophthalmology practice may not routinely run: hepatitis B testing (the drug is contraindicated with active infection, and HBsAg-negative but core-antibody-positive patients need a liver specialist’s input before and during treatment), evaluation for active disease or untreated latent tuberculosis, and baseline liver transaminases and bilirubin, with caution advised above 1.5 times the upper limit of normal. Any active infection, including a localized one, should resolve before starting. Live or live-attenuated vaccines are not recommended during treatment and should be completed beforehand.
- Hepatitis B surface antigen and core antibody testing; contraindicated in active HBV infection.
- Tuberculosis evaluation, including testing for latent infection.
- Baseline liver transaminases (AST/ALT) and bilirubin.
- Confirm no active infection, and that live vaccines are up to date or deferred until after treatment.
None of this is unusual for a prescriber already comfortable with biologic immunomodulators, but it is new territory for a thyroid eye disease practice built around corticosteroid tapers and infusion scheduling. In a co-managed patient, the practical answer is usually division of labor: the endocrinologist or rheumatologist already managing the patient’s other immunomodulatory therapy often owns the screening and monitoring, while the ophthalmologist tracks the orbital findings the drug is meant to move.
Where Enspryng sits beside two infused biologics
Three approved thyroid eye disease biologics
| Enspryng (satralizumab) | Tepezza (teprotumumab) | Lumvoa (veligrotug) | |
|---|---|---|---|
| Company | Genentech (Roche Group) | Amgen (via Horizon Therapeutics) | Viridian Therapeutics |
| U.S. approval | 16 Oct 2026, for TED; first approved 2020 for NMOSD | Jan 2020, for TED | 26 Jun 2026, for TED (active and chronic) |
| Administration | Subcutaneous; self- or caregiver-injected at home after training | IV infusion; 8 infusions over about 21 weeks in a clinic | IV infusion; 5 infusions over 12 weeks in a clinic |
| Mechanism | Anti-IL-6 receptor monoclonal antibody | Anti-IGF-1 receptor monoclonal antibody | Anti-IGF-1 receptor monoclonal antibody |
| Pivotal evidence | SatraGO-1 and -2, 258 adults; one of two trials met its primary endpoint | Two placebo-controlled trials, 170 adults with active TED | THRIVE and THRIVE-2, both met primary and secondary endpoints |
| Notable safety signal | Serious infection risk; hepatitis B and TB screening required | Hearing impairment (can be permanent); hyperglycemia; IBD flares | Hearing impairment; hyperglycemia; infusion reactions (~9%) |
| Billing | No TED-specific code confirmed; NMOSD use billed as unclassified (J3590) | HCPCS J3241, established Medicare Part B buy-and-bill | New in 2026; billing code not yet confirmed in public sources |
Teprotumumab and veligrotug particulars from their own labels and public billing records; Enspryng particulars from Roche’s 16 October 2026 announcement and the Enspryng prescribing information. Prescribe and bill from the current labels and payer policies, not this table.
The honest framing is that Enspryng does not obviously out-perform either infused option on the evidence disclosed so far — Lumvoa’s THRIVE program met every endpoint it set, and Tepezza has a decade of post-marketing experience behind it. What Enspryng changes is where the treatment happens and who gives it. For a patient who lives far from an infusion center, who has a needle-free aversion to IV access, or whose schedule cannot accommodate eight visits every three weeks, a once-monthly home injection is a meaningfully different proposition even without a head-to-head efficacy win.
Coverage: approved does not yet mean paid for
Regulatory authorization and reimbursement are different things, and the gap here is real. Teprotumumab has had its own Medicare HCPCS code, J3241, since October 2020, billed per 10mg under the medical benefit with the usual buy-and-bill mechanics of an infused specialty drug. Enspryng’s existing NMOSD use has instead been billed under J3590, an unclassified-biologic code that leaves pricing to payer-by-payer negotiation rather than a published Medicare rate. No source found in reporting this story shows a thyroid-eye-disease-specific code, a Medicare national coverage determination, or a published list price for the TED indication; one Medicaid policy document covering Enspryng’s CSU-adjacent use (for a different drug in the same mechanistic class) explicitly treats indications outside its approved scope as experimental and non-covered until updated, which is the posture a payer could plausibly take here too until its own policy catches up to the October approval.
That has a practical consequence for how the drug reaches a patient: because it is self-administered, Enspryng is more likely to route through a specialty pharmacy and the pharmacy benefit than through a hospital or infusion-center’s buy-and-bill process. A practice considering Enspryng for a TED patient should expect a benefits-investigation and prior-authorization step before the first shipment, not an answer at the point of prescribing — Genentech's own enrollment materials describe exactly that kind of benefits-verification service, which is itself an acknowledgment that coverage is not yet routine.
What changes in the clinic and at the infusion center
- Patient selection. Best considered for patients who can reliably self-inject or have a willing trained caregiver, who have access barriers to an infusion center, or who want to avoid IV access and its attendant risks — not necessarily for a patient already responding well to an infused option.
- New screening workflow. Hepatitis B, TB and liver-enzyme testing before the first dose is new ground for most ophthalmology practices managing TED; co-management with the endocrinologist or rheumatologist already running the patient's other immunomodulatory care is the practical path.
- Training burden shifts, it doesn't disappear. A clinician still has to teach injection technique and recognize when a patient needs to return to in-person monitoring of proptosis, diplopia and optic nerve function — outcomes a home injection cannot self-report.
- Set expectations on the evidence. One of two pivotal trials did not clear statistical significance; that belongs in the informed-consent conversation alongside the convenience argument.
- Confirm coverage before switching anyone. With no TED-specific code or established payer policy, a stable patient on an infused biologic should not be moved to Enspryng on the assumption that benefits will follow.
From a 2020 NMOSD approval to a second indication
- Aug 2020
Enspryng approved for NMOSD
FDA approves satralizumab-mwge for adults with AQP4-antibody-positive neuromyelitis optica spectrum disorder.
- Jan 2020
Tepezza approved for TED
Teprotumumab becomes the first FDA-approved drug for thyroid eye disease.
- ~2024
SatraGO program begins
Genentech initiates SatraGO-1 and SatraGO-2, identical Phase 3 trials of satralizumab in thyroid eye disease.
- 26 Jun 2026
Lumvoa approved for TED
Viridian's veligrotug becomes the third approved biologic for the condition, labeled for both active and chronic disease.
- Jun 2026
FDA grants priority review
Genentech's supplemental application for Enspryng in TED enters priority review.
- 16 Oct 2026
FDA approves the TED indication
Enspryng becomes the first at-home injectable approved for thyroid eye disease.
- Ahead
MOGAD review pending
A separate FDA decision on satralizumab for MOGAD is reported under priority review, with a decision expected in early 2027; not yet approved.
Sources & further reading
- Roche, “FDA approves Roche's Enspryng as first at-home subcutaneous treatment for thyroid eye disease,” media release, 16 October 2026. roche.com
- Enspryng (satralizumab-mwge) injection, U.S. prescribing information, Genentech, Inc. gene.com
- ClinicalTrials.gov, SatraGO-1 trial record (NCT05987423). clinicaltrials.gov
- ClinicalTrials.gov, SatraGO-2 trial record (NCT06106828). clinicaltrials.gov
- Healio, “FDA approves Enspryng for thyroid eye disease.” healio.com
- Ophthalmology Times, “FDA approves subcutaneous Enspryng for TED.” ophthalmologytimes.com
- Review of Optometry, “Satralizumab shows clinically meaningful improvements in TED.” reviewofoptometry.com
- HCPLive, “FDA Approves Veligrotug-vvze (Lumvoa) for Thyroid Eye Disease.” hcplive.com
- Centers for Medicare & Medicaid Services, HCPCS code J3241 (teprotumumab-trbw), effective October 1, 2020. businesswire.com
undefined
Frequently asked questions
Did Enspryng's thyroid eye disease trials both succeed?
No. Across the identically designed SatraGO-1 and SatraGO-2 trials, only SatraGO-2 met its Week 24 proptosis-response primary endpoint (52.9% vs 23.4% on placebo, P=0.0011). SatraGO-1 missed it (49.0% vs 31.2%, P=0.0715), which investigators attributed to an unusually high placebo response. FDA approved the drug on the combined program.
What screening does a patient need before starting Enspryng?
Hepatitis B testing (it is contraindicated in active infection), evaluation for active or untreated latent tuberculosis, and baseline liver transaminases and bilirubin. Any active infection should resolve first, and live or live-attenuated vaccines should be completed before starting, since they are not recommended during treatment.
Is Enspryng covered for thyroid eye disease yet?
Not confirmed. Enspryng's existing neuromyelitis optica coverage has used the unclassified biologic code J3590 rather than a drug-specific HCPCS code, and no thyroid-eye-disease-specific payer policy or permanent code has been identified. Confirm current coverage with the payer and with Genentech's access-support program before a patient starts.
